The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results